Geneticists have a better understanding of how prehistoric pairings unfolded, with new research suggesting they were mostly ...

Q4 2025 earnings call highlights: 2026 revenue outlook, Bako/StrataDx deals, AI pathology gains, and customer-loss risks—read now.

As of Friday, February 27, Fulgent Genetics, Inc.’s FLGT share price has dipped by 31.34%, which has investors questioning if this is right time to buy.

A study shows that interbreeding between the two species occurred primarily in one direction, and the origin of this bias is ...

Myriad Genetics (NASDAQ:MYGN) executives highlighted fourth quarter and full-year 2025 results alongside a slate of planned ...

Opus Genetics targets inherited retinal diseases with one-dose AAV gene augmentations. Read why IRD stock is a Buy.

Scientists have identified how specific genetic changes function in cells to influence disease risk and other human health ...

Fulgent Genetics Inc (FLGT) reports a 14% annual revenue increase, strategic acquisitions, and new market opportunities despite facing significant customer revenue loss.

Myriad Genetics (MYGN) surged 24% in premarket trading on Tuesday after reporting a quarterly earnings beat and outlining a 2026 revenue target of $860 million to $880 million while highlighting ...

Duckweed is the fastest-growing flowering plant, but new knowledge of duckweed genetics discovered by Adelaide University researchers could lead to even faster growing rates. The research team, led by ...